학술논문

Patient-reported outcome (PRO) measures at 12 months (12M) in a real-world cohort of people living with HIV (PLWH) with a high prevalence of comorbidities receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Europe, Canada, and Israel
Document Type
Journal
Source
HIV MEDICINE; OCT 2021, 22 p108-p110, 3p. Supplement: 3
Subject
Language
English
ISSN
14681293